GleamWall
中文EN

BNTX BioNTech SE IFRS Annual reports only

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1776985 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY4.3%
TTM net income YoY-70.8%
TTM EPS YoY-69.7%
Revenue 3-yr CAGR-45.1%
Net income 3-yr CAGR—

Margins

Gross margin77.6%
Operating margin-49.0%
Net margin-39.6%
FCF margin9.8%
EBITDA margin-35.6%

Returns

ROE-5.9%
ROA-5.1%
ROIC (approx.)-10.5%
Asset turnover0.13x

Leverage & solvency

Liabilities / assets12.6%
Debt / equity0.00x
Current ratio7.54x
Interest coverage-98.94x

Cash quality & payout

Operating cash flow / net income-0.40x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue6.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: EUR FY20252025-12-31FY20242024-12-31
Income statement
Revenue2.87B2.75B
Cost of revenue641.80M541.30M
Gross profit2.23B2.21B
R&D expense2.10B2.25B
SG&A expense514.40M531.10M
Operating income-1.40B-1.31B
Interest expense14.20M16.90M
Pretax income-1.05B-677.70M
Income tax85.30M-12.40M
Net income-1.14B-665.30M
EBITDA-1.02B-1.02B
EPS (basic)-4.70-2.77
EPS (diluted)-4.70-2.77
Weighted avg. shares (diluted)241.70M240.40M
Balance sheet
Cash & equivalents7.68B9.76B
Receivables924.20M1.46B
Inventory110.70M283.30M
Current assets16.15B18.80B
PP&E, netmay include right-of-use assets (IFRS)1.08B935.30M
Goodwill367.90M380.60M
Total assets21.99B22.53B
Current liabilities2.14B2.52B
Total liabilities2.76B3.12B
Shareholders' equity19.22B19.41B
Shares outstanding251.33M239.97M
Cash flow statement
Operating cash flow456.00M207.70M
Capital expenditure175.10M286.50M
Free cash flow280.90M-78.80M
Investing cash flow-2.47B-2.08B
Financing cash flow-52.90M-45.90M
Depreciation & amortization382.80M298.00M
Stock-based compensation106.20M100.90M
Dividends paid—0

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.